Dana Delaski, MSN, FNP-BC, shares insights on how once-daily ruxolitinib, self-injected rusfertide, and givinostat will transform PV clinic workflows.
|Articles|May 5, 2014
Publications for Patients and Caregivers
The Leukemia & Lymphoma Society (LLS) is pleased to present the following updated publications for patients and caregivers
Advertisement
The Leukemia & Lymphoma Society (LLS) is pleased to present the following updated publications for patients and caregivers:
The Lymphoma Guide:Information for Patients and Caregivers
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
To view PDFs or order copies of these free publications in English or Spanish, use the links above. To access all of our free publications, visit
- (800) 955-4572
- Live chat
Advertisement
Related to this article
FDA approves sNDA for taletrectinib (Ibtrozi) in ROS1+ NSCLC with updated DOR of nearly 50 months.
Gigi Jameel, APRN, discusses supportive care interventions, ADT toxicity management, and team collaboration in prostate cancer care.
Patients often use AI to read test results, but AI can misinterpret data and cause panic. Learn why human context remains critical.
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.
KEYNOTE-564 data show adjuvant pembrolizumab maintains DFS and OS benefits in ccRCC. Review key nursing takeaways and safety outcomes.
ASTRO updated its pancreatic cancer radiation guideline. Dr Michael Chuong shares direct takeaways on nursing roles in multidisciplinary care.
NCCN survey data show 100% of cancer centers face drug shortages, with ifosfamide and carboplatin critical.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Oncology Experts Discuss On-Body Subcutaneous Isatuximab in Multiple Myeloma
2
Why Using AI to Interpret Mammogram Results Can Cause Unnecessary Panic
3
FDA Approves sNDA for Taletrectinib in ROS1+ NSCLC
4
Prostate Cancer Care: ADT Management and APP Guidance
5